A phase II study of the VEGFR- and FGFR-inhibitior Dovitinib (TKI258) in patients with refractory advanced or metastatic renal cell cancer previously treated with VEGFR- or mTOR-targeted therapy

Titel:: A phase II study of the VEGFR- and FGFR-inhibitior Dovitinib (TKI258) in patients with refractory advanced or metastatic renal cell cancer previously treated with VEGFR- or mTOR-targeted therapy
Dokumenttyp:: Meeting Abstract
Autor(en):: Grunwald, V; Retz, M; Fenner, M; Wang, Y; Chang, J; Kay, A; Zuern, C; Gschwend, J
Zeitschriftentitel:: Onkologie
Jahr:: 2011
Band / Volume:: 34 6
Seitenangaben Beitrag:: 11-11
Sprache:: eng
Print-ISSN:: 0378-584X
TUM Einrichtung:: Urologische Klinik und Poliklinik
BibTeX

Vorkommen: